Key takeaways
- CDC’s adult RSV vaccine page (updated Feb. 20, 2026) still says one dose. If you already got Arexvy, Abrysvo, or mResvia, you do not get another this season unless CDC changes that.
- Everyone 75 and older is in. Ages 50–74 are in only with increased risk of severe RSV — heart or lung disease, certain diabetes complications, immune compromise, nursing home, and a longer clinical list. Isolated high blood pressure is not that list.
- The useful calendar is late summer into early fall (August–October in most of the continental U.S.). You can get it in March. You just wasted the months RSV is actually circulating.
RSV vaccine season at the pharmacy looks like flu season because the same counter is booking both. It is not the same product class. Influenza shots are rebuilt most years because the viruses drift. The three licensed adult RSV vaccines are a one-and-done recommendation right now. CDC’s public page is blunt about it: if you already received an RSV vaccine, including last year, do not get another at this time. Source: CDC, Vaccines for Adults (RSV).
The cold that “isn’t COVID and isn’t flu” in January is often RSV. In healthy working-age people it is usually a miserable week. In older adults and in people with specific chronic disease it is a hospitalization virus. That gap is why the recommendation is age-plus-risk, not “everyone with a Costco membership.”
Not the flu calendar
RSV in most of the continental United States ramps in fall and peaks in winter. Timing slips year to year. CDC still tells eligible adults who have never been vaccinated to aim for late summer and early fall — August through October — so antibody is up before the wave, not during it. You can get the dose any month. The “any month” line is for people who missed the window, not a reason to treat it like a January New Year’s errand.
Protection in adults 50 and older has held at least two years in the data CDC cites. Arexvy and Abrysvo were licensed in May 2023; mResvia in June 2024. The agency is still watching duration. “Not annual” is the current operational rule, not a forever promise. When they add a booster, it will show up on that same page. A pharmacy text that says “time for your RSV” is a scheduling script.
Who CDC means
Two buckets, as of the Feb. 20, 2026 adult page and the clinical overview:
- 75 and older: one dose. Age is the risk factor.
- 50–74: one dose only if you are at increased risk of severe RSV.
Under 50 as an adult: this article is not your on-ramp unless you are pregnant (different product, different weeks) or you are asking about an infant antibody. Do not walk into a retail clinic and demand the geriatric RSV shot because TikTok said “respiratory season.”
Do not get it if you have had a severe allergic reaction to a component of that vaccine. Package inserts exist for a reason. Moderate or severe illness: wait until you are not flattened. A mild cold is not a stop.
The 50–74 list
CDC’s clinical overview (Aug. 18, 2025) is the list pharmacists are supposed to use, not a vibe. Increased-risk conditions include:
- Chronic cardiovascular disease — heart failure, coronary disease, congenital heart disease. Isolated hypertension is called out as not enough by itself.
- Chronic lung or respiratory disease — COPD, emphysema, asthma, interstitial lung disease, cystic fibrosis.
- End-stage renal disease or dialysis / other renal replacement.
- Diabetes with kidney, nerve, or eye damage, or diabetes treated with insulin or an SGLT2 inhibitor.
- Neurologic or neuromuscular disease that impairs airway clearance or respiratory muscle strength. A remote stroke with no swallowing problem is not automatically in.
- Chronic liver disease such as cirrhosis.
- Chronic hematologic disease such as sickle cell or thalassemia.
- Severe obesity (BMI at or above 40).
- Moderate or severe immune compromise.
- Living in a nursing home.
- Other chronic conditions or frailty a clinician judges would worsen viral respiratory disease, including some remote/rural settings where a transfer for severe RSV is ugly.
Full write-up: CDC, Clinical Overview of RSV. Patient attestation is enough for the risk factor. CDC tells vaccinators not to refuse you because you did not bring a cardiology note. That sentence exists because clinics were doing exactly that.
If you are 62, walk daily, and your only “condition” is a statin for cholesterol, you are not in the 50–74 bucket on this list. The 2023 “talk it over with your doctor if you are 60+” shared-decision era is not the current adult rule.
Three shots, no favorite
FDA-licensed for adults: GSK’s Arexvy, Pfizer’s Abrysvo, Moderna’s mResvia. CDC has no preference among them for adults 50 and older. One intramuscular dose. They are not interchangeable with the infant antibody products. They are not compounded peptides from a telehealth cooler. If a clinic is mixing mystery vials, that is a different scandal we already mapped: compounded GLP-1 shots.
Common side effects: sore arm, fatigue, headache, fever, muscle or joint pain, GI upset. Usually mild. Report unexpected events to VAERS. V-safe exists for RSV too if you want CDC’s after-shot check-ins.
Guillain-Barré syndrome has been a safety topic in post-licensure surveillance for some RSV vaccines in older adults. That is why CDC keeps a safety page and why “one dose, high-risk groups” is the shape of the recommendation. Read CDC RSV vaccine safety if that is your actual question. Do not crowdsource it from a comments section.
Pregnancy and infants
Infants do not get the adult RSV vaccine as their primary shield. CDC’s path is either Pfizer’s Abrysvo given to the pregnant person during weeks 32–36, or a long-acting antibody given to the baby after birth (nirsevimab, and in current guidance clesrovimab is in the infant conversation). Nirsevimab is also used for some children 8–19 months heading into a second RSV season. Do not stack maternal vaccine and infant antibody as a DIY “more is safer” plan; that is a clinician timing problem, not a coupon.
If you are 28 weeks and a pharmacy offers “the RSV shot,” ask which product and which CDC pathway. Abrysvo is the maternal one. Arexvy and mResvia are not that pathway.
Same day as flu
You can usually receive RSV vaccine the same visit as influenza and COVID shots. Sore arms stack. That is logistics, not a medical requirement to combine them. If you already had RSV vaccine in 2023 or 2024, the flu clinic should skip the RSV SKU and still offer flu.
A “respiratory vaccine bundle” email in August is how chains fill chairs. Read the ages on the booking page. A 51-year-old with no listed risk who gets RSV because the dropdown defaulted to yes has received a dose CDC did not target. CDC will still count it as your one dose.
Paying for it
ACIP-recommended adult immunizations are supposed to be $0 in-network under many commercial plans and, for Medicare, under the Inflation Reduction Act’s adult vaccine cost-sharing rules for recommended shots billed the Part D way. HDHP / HSA households still need the claim coded as preventive, not as a random office visit with a surprise bill. The 2026 HSA dollar caps are a different machine: HSA contribution limits for 2026.
Uninsured: CDC’s “how to pay” and “where to find vaccines” pages are the non-advertising start. A cash retail price that looks like a plane ticket is a reason to call the health department, not a reason to skip if you are 78.
Bring the year you got the last RSV dose, if you got one. The EHR and the pharmacy chain often do not talk. “I think I got something in the fall” is how people get a second adult dose nobody asked them to get.
Education from CDC pages dated into 2026, not personal medical advice. Recommendations move. If you are in the age or risk group, the person who should match product, timing, and your chart is a clinician or pharmacist looking at that chart — not a headline.
